GLP-1 compounding: questions clinics should ask before prescribing

Start with the patient’s medical need

A clinic discussing compounded GLP-1 medication with a pharmacy needs more than a price and a concentration. First establish the individual patient’s medical need and whether an available FDA-approved drug can meet it. FDA advises that compounded drugs be used only when a patient’s medical needs cannot be met by an FDA-approved drug.

A compounded preparation does not become FDA-approved because it contains an ingredient also found in an approved medicine. Avoid describing it as the same as an approved product. The prescribing discussion should distinguish the proposed preparation from the approved product and address its particular uncertainties.

Recheck the rules instead of relying on shortage-era assumptions

FDA’s April 1, 2026 update states that semaglutide and tirzepatide do not appear on its drug shortage list or the 503B bulks list. Earlier shortage-related compounding policies should not be treated as ongoing permission for routine copies. Check the current FDA information when evaluating a request; this article’s sources were reviewed on November 7, 2026.

For section 503A, FDA highlights both patient-specific prescriptions and restrictions on regular or inordinate compounding of essentially copies of commercially available drugs. Its update discusses a prescriber-determined, documented change that produces a significant difference for an identified patient. A patient-specific prescription alone does not settle every eligibility requirement.

Adding another ingredient is not an automatic solution. FDA specifically explains that a combination containing semaglutide and another active ingredient, such as vitamin B12, may still be considered essentially a copy. Ask the pharmacist to review the precise proposed formulation and the current requirements, rather than using a standard justification for every patient.

• Check FDA’s current GLP-1 compounding update

Confirm ingredient identity and label clarity

Ask what exact active ingredient and chemical form are proposed. FDA warns that semaglutide sodium and semaglutide acetate are different active ingredients from the form in approved drugs and says it is not aware of a lawful basis for their use under the applicable compounding conditions. Do not assume that every product described as a GLP-1 has the same regulatory status.

FDA has also reported errors involving compounded injectable semaglutide, including confusion between amounts of drug, volumes and syringe units. A clinic should resolve unclear instructions with the prescriber and dispensing pharmacist. This article provides no dose calculations, conversion instructions or administration schedule.

• FDA information on unapproved GLP-1 products

Agree on responsibilities before arranging a prescription

Use the initial pharmacy conversation to make the handoff explicit:

• Identify the compounding facility, dispensing pharmacy and clinical contact.
• Confirm which patient-specific information and documentation the pharmacist needs to assess the request.
• Reconcile the ingredient, concentration, dosage form, quantity and directions through the prescribing workflow.
• Identify who will provide product-specific counseling and written storage and beyond-use instructions.
• Arrange a clear contact for shipment concerns, product complaints and medication questions.

Confirm acceptance of the specific request

For a Liberty inquiry about tirzepatide, discuss the patient-specific request with the pharmacy before communicating acceptance, pricing or delivery expectations. Semaglutide is discussed here as regulatory context, not as a statement that Liberty offers it. The prescriber and pharmacist must review the actual request and current requirements.

Start a clinic discussion by calling (888) 448-0549 or emailing contact@libertycompounding.com. Ask which channel to use for a prescription and patient information. This article is general education, not a dosing guide or a recommendation to use compounded medication.

• Tirzepatide pharmacy guide for clinics